Form 4: Insmed CFO Sara Bonstein Executes Stock Sale

Insmed Chief Financial Officer Sara Bonstein sold 2,404 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• CFO Sara Bonstein sold 2,404 shares of Insmed Inc (INSM) common stock.
• The transaction occurred on June 3, 2026, at a price of $102.27 per share.
• The sale was conducted to satisfy tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• Following this transaction, the reporting person retains beneficial ownership of 69,082 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax requirements related to equity compensation.

Positives

• The sale was non-discretionary, specifically executed to cover tax liabilities rather than reflecting a change in market sentiment by the executive.

Negatives

• Reduction in the direct equity stake held by the Chief Financial Officer.

Risks

• General market volatility affecting the valuation of executive equity holdings.

Future Outlook

No forward-looking guidance or strategic outlook was provided in this regulatory filing.

Industry Context

StockSavvy.ai notes that routine insider sales to cover tax obligations upon RSU vesting are standard corporate practice and typically do not signal a lack of confidence in the company's long-term prospects.

Comparison to Industry Standards

• The transaction aligns with standard executive compensation practices in the biotechnology sector where equity-based incentives are common.

Stakeholder Impact

• Minimal impact on shareholders as the sale was for tax compliance purposes.

Key Dates

Keywords

Insmed, INSM, Insider Trading, Form 4, CFO, Equity Compensation